Clozapine, atypical antipsychotics, and the benefits of fast-off D 2 dopamine receptor antagonism

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 385, Issue 4, 2012, Pages 337-372

  Vauquelin, Georges ^a   Bostoen, Sophie ^a   Vanderheyden, Patrick ^a   Seeman, Philip ^b  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antipsychotics; Clozapine; D 2 dopamine receptor; Dissociation kinetics; Schizophrenia; Simulations

Indexed keywords

2 ETHOXY 1(2H) QUINOLINECARBOXYLIC ACID ETHYL ESTER; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT;

AKATHISIA; BINDING KINETICS; BRADYKINESIA; CALCIUM SIGNALING; DISSOCIATION; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DRUG DETERMINATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SCREENING; DRUG WITHDRAWAL; DYSTONIA; HUMAN; IC 50; IN VITRO STUDY; LIGAND BINDING; NONHUMAN; PARKINSONISM; PATIENT COMPLIANCE; POSITRON EMISSION TOMOGRAPHY; PSYCHOPHARMACOTHERAPY; RECEPTOR AFFINITY; RECEPTOR OCCUPANCY; REVIEW; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREMOR;

ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOPAMINE ANTAGONISTS; HUMANS; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA;

EID: 84862869593     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-012-0734-2     Document Type: Review

References (292)

1. Abi-Dargham A, Laruelle M (2005) Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiat 20:15-27 (Pubitemid 40092387)
2. 2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A 97:8104-8109 (Pubitemid 30460780)
3. 2 receptors in antipsychotic response: a double-blind PET study in schizophre-nia. Neuropsychopharmacol 32:1209-1215 (Pubitemid 46788848)
4. Agnati LF, Guidolin D, Guescini M, Genedani S, Fuxe K (2010) Understanding wiring and volume transmission. Brain Res Rev 64:137-159
5. 2 autoreceptors in the absence ofautoinhibition. J Pharmacol Exp Ther 257:19-25
6. 2 dopamine receptor colocalization in neo-striatal neurons. Nat Neurosci 3:226-230 (Pubitemid 30140783)
7. Akam E, Strange PG (2004) Inverse agonist properties of atypical antipsychotic drugs. Biochem Pharmacol 67:2039-2045 (Pubitemid 38595485)
8. Albin RL, Young AB, Penney JB (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci 12:366-375 (Pubitemid 19238787)
9. Allen JA, Halverson-Tamboli RA, Rasenick MM (2007) Lipid raft microdomains and neurotransmitter signalling. Nat Rev Neurosci 8:128-140 (Pubitemid 46146951)
10. Alphs LD, Lee HS (1991) Comparison ofwithdrawal oftypical and atypical antipsychotic drugs: a case study. J Clin Psychiat 52:346-348
11. Amalric M, Koob GF (1993) Functionally selective neurochemical afferents and efferents of the mesocorticolimbidopamine system. Prog Brain Res 99:209-226 (Pubitemid 24015896)
12. 2-adrenoceptor agonist bronchodilator. Life Sci 52:2145-2160
13. Anderson GP, Lindén A, Rabe KF (1994) Why are long-acting beta-adrenoceptor agonists long-acting? Eur Respir J 7:569-578 (Pubitemid 24099018)
14. Angrist B, Van Kammen DP (1984) CNS stimulants as a tool in the study of schizophrenia. Trends Neurosci 7:388-390 (Pubitemid 14010235)
15. 2 receptor dimer forma-tion: evidence from ligand binding. J Biol Chem 276:22621-22629
16. Arnt J, Skarsfelt T (1998) Do novel antipsychotics have similar phar-macological characteristics? A review ofevidence. Neuropsycho-pharmacol 18:63-101 (Pubitemid 28026679)
17. Arunlakshana O, Schild HO (1959) Some quantitative uses of drug antagonists. Brit J Pharmacol 14:48-58
18. Baldessarini RJ, Frankenburg FR (1991) Clozapine. A novel antipsy-chotic agent. N Engl J Med 324:74-54
19. Baron JC, Martinot JL, Cambon H, Boulenger JP, Poirier MF, Caillard V, Blin J, Huret JD, Loch C, Maziere B (1989) Striatal dopamine receptor occupancy during and following withdrawal from neu-roleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology 99:463-472 (Pubitemid 19273100)
20. 2 dopamine receptors in human Y-79 retinoblastoma cells. Mol Pharmacol 39:650-658
21. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG (2005) An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior Cell 122:261-273 (Pubitemid 41032989)
22. Bédard P, Larochelle L, Parent A, Poirier LJ (1969) Dopamine and serotonin in the striatum of the cat Effect of lesions of the intra-laminar nuclei. Arch Neurol 20:239-242
23. Ben-Jonathan N, Hnasko R (2001) Dopamine as a prolactin (PRL) inhibitor. Endocrine Rev 22:724-763 (Pubitemid 34214293)
24. Björklund A, Falck B, Hromek F, Owman C, West KA (1970) Identi-fication and terminal distribution of the tubero-hypophyseal monoamine fibre systems in the rat by means of stereotaxic and microspectrofluorimetric techniques. Brain Res 17:1-23
25. Black JW, Leff P (1983) Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 220:141-162 (Pubitemid 14217337)
26. s. J Phar-macol Exp Ther 294:539-547 (Pubitemid 30490827)
27. 2 receptors. J Phar-macol Exp Ther 302:381-389 (Pubitemid 34680462)
28. 3 partial agonist. J Pharmacol Exp Ther 315:1278-1287 (Pubitemid 41635416)
29. Burt DR, Creese I, Snyder SH (1977) Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 196:326-328 (Pubitemid 8076966)
30. Carlsson A, Carlsson ML (2006) A dopaminergic deficit hypothesis of schizophrenia: thepathtodiscovery. DialogClinNeurosci 8:137-142
31. Caron MG, Beaulieu M, Raymond V, Gagne B, Drouin J, Lefkowitz RJ, Labrie F (1978) Dopaminergic receptors in the anterior pitu-itary gland: correlation of [ H]dihydroergocryptine binding with the dopaminergic control of prolactin release. J Biol Chem 253:2244-2253 (Pubitemid 8328208)
32. 2L receptors. Neuropsy-chopharmacol 27:723-726 (Pubitemid 35335890)
33. 2A receptor revisited: evidence for physical separation of two signaling cascades. J Biol Chem 283:9276-9288
34. Charlton S, Vauquelin G (2010) Elusive equilibrium: the challenge of interpreting receptor pharmacology using calcium assays. Brit J Pharmacol 161:1250-1265
35. 2 dopamine receptors. Mol Pharmacol 45:51-60 (Pubitemid 24042282)
36. Christopoulos A, Parsons AM, Lew MJ, El-Fakahany EE (1999) The assessment of antagonist potency under conditions of transient response kinetics. Eur J Pharmacol 382:217-227 (Pubitemid 29509837)
37. 3 and D4.4 receptors expressed in Chinese hamster ovary cells. Brit J Pharmacol 127:1135-1144 (Pubitemid 29326636)
38. Copeland RA (2010) The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety. Expert Opin Drug Discov 5:305-310
39. Copeland RA, Pompliano DL, Meek TD (2006) Drug-target residence time and its implications for lead optimization. Nat Rev Drug Disc 5:730-739 (Pubitemid 44323700)
40. Cragg SJ, Rice ME (2004) DAncing past the DAT at a DA synapse. Trends Neurosci 27:270-277 (Pubitemid 38529955)
41. Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizo-phrenic drugs. Science 192:481-483
42. Csernansky JG, Murphy GM, Faustman WO (1991) Limbic/mesolim-bic connections and the pathogenesis of schizophrenia. Biol Psy-chiat 30:383-400
43. Curran C, Byrappa N, McBride A (2004) Stimulant psychosis: sys-tematic review. Brit J Psychiat 185:196-204
44. Dal Toso R, Sommer B, Ewert M, Herb A, Pritchett DB, Bach A, Shivers BD, Seeburg PH (1989) The dopamine D2 receptor: two molecular forms generated by alternative splicing. EMBO J 8:4025-4034 (Pubitemid 20066843)
45. Davis KL, Kahn RS, Ko G, Davidson M (1991) Dopamine in schizo-phrenia: a review and reconceptualization. Am J Psychiat 148:1474-1486
46. De Lean A, Stadel JM, Lefkowitz RJ (1980) A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor J Biol Chem 255:7108-7117 (Pubitemid 11232874)
47. Demaegdt H, Smitz L, De Backer J-P, Le MT, Bauwens M, Michotte Y Vanderheyden P, Vauquelin G (2008) Translocation of the insulin regulated aminopeptidase to the cell surface: detection by radio-ligand binding. Brit J Pharmacol 154:872-881 (Pubitemid 351821580)
48. Demaegdt H, Gard P, De Backer J-P, Lukaszuk A, Szemenyei E, Tóth G, Tourwé D, Vauquelin G (2011) Binding of "AT4 receptor" ligands to the insulin regulated aminopeptidase (IRAP) in intact Chinese hamster ovary cells. Mol Cell Endocrinol 339:34-44
49. Dowling MR, Charlton SJ (2006) Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor Brit J Pharmacol 148:1134-1142
50. Dreyer JK, Herrik KF, Berg RW, Hounsgaard JD (2010) Influence of phasic and tonic dopamine release on receptor activation. J Neu-rosci 30:14273-14283
51. 2 receptor antagonism and fast receptor dissociation prop-erties. Eur J Pharmacol 628:19-26
52. 2 dopamine receptor activation of a potassium channel in rat lactotrophs. J Physiol 462:563-578 (Pubitemid 23094495)
53. 2 dopamine receptor activation ofpotassium channels in identified rat lactotrophs: whole-cell and single-channel recording. J Neurosci 11:3727-3737
54. Eklind-Cervenka M, Benson L, Dahlström U, Edner M, Rosenqvist M, Lund LH (2011) Association of candesartan vs losartan with all-cause mortality in patients with heart failure. J Amer Med Assoc 305:175-182
55. Farah AJ (2005) Atypicality ofatypical antipsychotics. Clin Psychiatry 2005(7):268-274
56. Farde L (1996) The advantage ofusing positron emission tomography in drug research. Trends Neurol Sci 19:211-214 (Pubitemid 26167811)
57. 2 dopa-mine receptor occupancy in relation to extrapyramidal syndromes in patients being treated with neuroleptic drugs. Psychoph S 10:94-100
58. 11 C]raclopride. Arch Gen Psychiat 47:213-219 (Pubitemid 20086672)
59. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiat 49:538-544
60. 2 receptor hetero-dimerization in the mechanism of action of clozapine. Eur Neuropsychopharm 18:682-691
61. Fierens FLP, Vanderheyden PML, De Backer J-P, Vauquelin G (1999) Insurmountable angiotensin II AT1 receptor antagonists: the role oftight antagonist binding. Eur J Pharmacol 372:199-206 (Pubitemid 29251292)
62. Fierens F, Vanderheyden PML, Roggeman C, Vande Gucht P, De Backer J-P, Vauquelin G (2002) Distinct binding properties of the AT1 receptor antagonist [ H]candesartan to intact cells and membrane preparations. Biochem Pharmacol 63:1273-1279 (Pubitemid 34326471)
63. Fluxe K, Hökfelt T, Johansson O, Jonsson G, Lidbrink P, Ljungdahl A (1974) The origin of the dopamine nerve terminals in limbic and frontal cortex. Evidence for meso-cortico dopamine neurons. Brain Res 82:349-355
64. 2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: the-oretical implications. Psychopharmacology 175:473-480 (Pubitemid 39362046)
65. Furchgott RF (1966) The use of β-haloalkylamines in the differ-entiation of receptors and in the determination of dissociation constants ofreceptor-agonist complexes. Adv Drug Res 3:21-55
66. Furchgott RF, Bursztyn P (1967) Comparison of dissociation constants and of relative efficacy of selected agonists acting on parasympa-thetic receptors. Ann N Y Acad Sci 144:882-898
67. Gaddum JH, Hameed KA, Hathaway DE, Stephens FF (1955) Quan-titative studies of antagonists for 5-hydroxytryptamine. Q J Exp Physiol 40:49-74
68. Ganz MB, Pachter JA, Barber DL (1990) Multiple receptors coupled to adenylate cyclase regulate Na-H exchange independent of cAMP. J Biol Chem 265:8989-8992
69. 2long dopamine receptors expressed in recombinant cells. Brit J Pharmacol 118:1544-1550 (Pubitemid 26248811)
70. Garris PA, Ciolkowski EL, Pastore P, Wightman RM (1994) Efflux of dopamine from the synaptic cleft in the nucleus accumbens of the rat brain. J Neurosci 14:6084-6093 (Pubitemid 24307800)
71. o G proteins: evidence for agonist regulation of G protein selectivity Brit J Pharmacol 138:775-786 (Pubitemid 36390633)
72. 2Short: Gαo fusion protein expressed in Sf9 cells. FEBS Lett 545:155-160 (Pubitemid 36694693)
73. 2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizo-phrenia. Psychopharmacology 135:119-126 (Pubitemid 28055494)
74. 2 re-ceptor gene in alcoholism or schizophrenia-analysis using denaturing gradient gel-electrophoresis. J Amer Med Assoc 271:204-208 (Pubitemid 24041257)
75. Gerfen CR (1992) The neostriatal mosaic: multiple levels ofcompart-mental organization in the basal ganglia. Annu Rev Neurosci 15:285-320
76. 2S receptors. J Biol Chem 274:9238-9245
77. 2S receptor activation in BALB/c 3T3 cells. Mol Cell Biol 20:1497-1506 (Pubitemid 30100169)
78. short, hD4.2 and hD4.7 receptors in agonist-stimulated [ S]GTPγS binding assays. N-S Arch Pharmacol 361:498-504 (Pubitemid 30262598)
79. Ginovart N, Farde L, Halldin C, Swahn C-G (1997) Effect ofreserpine-induced depletion of synaptic dopamine on [ C]raclopride bind-ing to D2-dopamine receptors in the monkey brain. Synapse 25:321-325 (Pubitemid 27155142)
80. 2 receptors in vivo using positron emission tomography. J Neuro-chem 97:1089-1103
81. Graeser D, Neubig RR (1993) Compartmentation of receptors and guanine nucleotide-binding proteins in NG108-15 cells: lack of cross-talk in agonist binding among the alpha2-adrenergic, mus-carinic and opiate receptors. Mol Pharmacol 43:434-443 (Pubitemid 23082000)
82. Grießner M, Bröker P, Lehmann A, Ehrentreich-Förster E, Bier FF (2009) Detection of angiotensin II type 1 receptor ligands by a cell-based assay. Anal Bioanal Chem 395:1937-1940
83. 3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacol31:1027-1035
84. Guillin O, Abi-Dargham A, Laruelle M (2007) Neurobiology ofdopa-mine in schizophrenia. Int Rev Neurobiol 78:1-39
85. 2 receptor internalization on binding affinity of neuroimaging radiotracers. Neuropsychopharmacol 35:806-817
86. 2 receptor occupancy by an atypical neuroleptic. Psychiatry Res 82:147-160 (Pubitemid 28341799)
87. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY (1993) Improvement in cognitive functions and psychiatric symp-toms in treatment-refractory schizophrenic patients receiving clo-zapine. Biol Psychiat 34:702-712 (Pubitemid 23354783)
88. 2 dopamine receptors. Brit J Pharmacol 121:731-736 (Pubitemid 27260777)
89. Hamblin MW, Creese I (1983) Behavioral and radioligand binding evidence for irreversible dopamine receptor blockade by N-ethox-ycarbonyl-2-ethoxy-1,2- dihydroquinoline. Life Sci 32:2247-2255 (Pubitemid 13124062)
90. B receptors show different binding profiles in intact cells and cell membrane preparations. Eur J Pharmacol 345:339-342 (Pubitemid 28179577)
91. 11C) clozapine in the brain of rhesus monkey studied by positron emission tomography (PET). Psycho-pharmacology 89:248-252 (Pubitemid 16065507)
92. Hauber W (1998) Involvement ofbasal ganglia transmitter systems in movement initiation. Prog Neurobiol 56:507-540 (Pubitemid 28407570)
93. Heise CE, Sullivan S, Crowe PD (2007) Scintillation proximity assay as high-throughput method to identify slowly dissociating non-peptide ligand binding to the GnRH receptor. J Biomol Screen 12:235-239 (Pubitemid 46364424)
94. + currents and excitabil-ity via a novel PLC β1-IP3-calcineurin-signaling cascade. J Neuro-sci 20:8987-8995 (Pubitemid 32042899)
95. 2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents. J Neurosci 75:5222-5237
96. Hippius H (1989) The history ofclozapine. Psychopharmacology 99: S3-S5
97. Hippius H (1999) A historical perspective ofclozapine. J Clin Psychiat 60:S22-S23
98. Hrabctová S, Nicholson C (2004) Contribution of dead-space micro-domains to tortuosity of brain extracellular space. Neurochem Int 45:467-477 (Pubitemid 38739473)
99. 2 subfamily ofdopamine receptors. Cell Signal 8:453-459 (Pubitemid 26401842)
100. Ichise M, Meyer JH, Yonekura Y (2001) An introduction to PET and SPECT neuroreceptor quantification models. J Nuclear Med 42: 755-763 (Pubitemid 32453465)
101. Idanpaan-Heikkila J, Alhava E, Olkinuora M, Palva IP (1977) Agran-ulocytosis during treatment with clozapine. Eur J Clin Pharmacol 11:193-198
102. 2 receptors expressed in Chinese hamster ovary cells. Mol Pharmacol 49:560-566 (Pubitemid 26087822)
103. 4 receptor antagonists in the treatment of schizo-phrenia. Curr Opin Invest Dr 3:101-105 (Pubitemid 34552311)
104. 2 dopamine receptors are coupled to their effectors by Go. Proc Natl Acad Sci USA 98:3577-3582 (Pubitemid 32220887)
105. 2 receptor isoforms in cultured neurons reveals equipotent autoreceptor function. Neuropharmacology 50:595-605
106. 2 occupancy in low EPS-incidence drugs: PET evidence (abstract). Biol Psychiat 47(8 suppl):112
107. 2 receptor partial agonists display differential or contrasting char-acteristics in membrane and cell-based assays of dopamine D2 receptor signaling. Prog Neuro-Psychoph 31:348-356 (Pubitemid 46209412)
108. Jordan S, Regardie K, Johnson JL, Chen R, Kambayashi J, McQuade R, Kitagawa H, Tadori Y, Kikuchi T (2007b) In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling. J Psychopharmacol 21:620-627 (Pubitemid 47472726)
109. 2 dopamine receptor interacting proteins within the cortex. Mol Neurosci 17:299-301
110. Kabbani N, Hannan M, Levenson R (2005) Unravelling the dopamine receptor signalplex by DRIPs and DRAPS. Curr Proteom 2:209-224
111. 2 dopamine receptor and the binding site and binding affinities for agonists and antagonists. Proc Natl Acad Sci USA 101:3815-3820 (Pubitemid 38381061)
112. Kane J, Honigfeld G, Singer J, Meltzer H (1988a) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiat 45:789-796
113. Kane JM, Honigfeld G, Singer J, Meltzer H (1988b) Clozapine in treatment-resistant schizophrenics. Psychopharmacol Bull 24:62-67
114. 2 dopamine receptors mediate the potentiation of arachidonic acid release in Chinese hamster ovary cells. Mol Pharmacol 39:364-369
115. 2 receptors. Prog Neuropsychophar-macol Biol Psychiatr 27:1081-1090 (Pubitemid 37464954)
116. 2 receptors. Implications for atypical antipsychotic action. J Psychiatr Neurosci 25:161-166 (Pubitemid 30233553)
117. 2 receptor explain the action ofatypical antipsychotics?: a new hypothesis. Am J Psychiat 158:360-369 (Pubitemid 32205190)
118. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiat 156:286-293 (Pubitemid 29077120)
119. 2 receptor occupancy Arch Gen Psychiat 57:553-559 (Pubitemid 30349435)
120. 2 dopa-mine receptor binding differences of clozapine and haloperidol. J Neural Transm 86:163-173
121. Kawagoe KT, Garris PA, Wiedemann DJ, Wightman RM (1992) Regulation of transient dopamine concentration gradients in the microenvironment surrounding nerve terminals in the rat striatum. Neuroscience 51:55-64
122. Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature 277:93-96 (Pubitemid 9093798)
123. 2 recep-tors by aripiprazole in schizophrenia with PET and [ F]fallypride. Neuropsychopharmacol33:3111-3125
124. Kenakin TP (1993) Stimulus-response mechanisms. In: Kenakin TP (ed) Pharmacologic analysis of drug-receptor interactions. Raven, New York, pp 39-68
125. Kenakin T (1996) The classification of seven transmembrane receptors in recombinant expression systems. Pharmacol Rev 48:413-463 (Pubitemid 126782561)
126. Kenakin T (2003) Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol Sci 24:346-354 (Pubitemid 37315526)
127. Kenakin T, Jenkinson S, Watson C (2006) Determining the potency and molecular mechanism of action of insurmountable antago-nists. J Pharmacol Exp Ther 319:710-723
128. 2 receptors in post mortem human brain with [ I]epidepride. Brain Res 609:237-243 (Pubitemid 23136824)
129. 2 receptors by clozapine and quetiapine. Neuropsychopharmacol 3:1991-2001
130. 3 recep-tors by G protein-coupled kinases and beta-arrestins. J Biol Chem 276:37409-37414
131. Kinon BJ, Lieberman JA (1996) Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology 124:2-34 (Pubitemid 26111436)
132. Kjeldsen SE, Stålhammar J, Hasvold P, Bodegard J, Olsson U, Russell D (2010) Effects of losartan vs candesartan in reducing cardio-vascular events in the primary treatment of hypertension. J Hum Hypertens 24:263-273
133. Koepp MJ, Gunn RN, Lawrence AD, Cunningham VJ, Dagher A, Jones T, Brooks DJ, Bench CJ, Grasby PM (1998) Evidence for striatal dopamine release during a video game. Nature 393:266-268 (Pubitemid 28261725)
134. Korner M, Gilon C, Schramm M (1982) Locking of hormone in the beta-adrenergic receptor by attack on a sulfhydryl in an associated component. J Biol Chem 257(7):3389-3396 (Pubitemid 12077125)
135. Kortekaas R, Maguire RP, Cremers TI, Dijkstra D, van Waarde A, Leenders KL (2004) In vivo binding behavior of dopamine re-ceptor agonist (+)-PD 128907 and implications for the "ceiling effect" in endogenous competition studies with [ C]raclopride-a positron emission tomography study in Macaca mulatta. J Cer-ebr Blood F Met 24:531-535 (Pubitemid 38608285)
136. 4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. Arch Gen Psychiat 4:567-572 (Pubitemid 27258555)
137. Langlois X, Megens A, Lavreysen H, Wouters R, Peeters L, te Riele P, Hendrickx H, Mahieu M, de Bruyn M, Macdonald G (2010) Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia. Poster, presented at the 23nd Congress of European College of Neuropsychopharma-cology; Amsterdam, 9/2010. EurNeuropsychopharmacol20:S502
138. Laruelle M (2000) Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cerebr Blood F Met 20:423-451 (Pubitemid 30164887)
139. Laruelle M (2003) Dopamine transmission in the schizophrenic brain. In: Weinberger DR, Hirsch S (eds) Schizophrenia, 2nd edn. Blackwell Publishing, Oxford, pp 365-387
140. 2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacol 17:162-174 (Pubitemid 27365957)
141. Laruelle M, Iyer RN, Al-Tikriti MS, Zea-Ponce Y, Malison R, Zoghbi SS, Baldwin RM, Kung HF, Charney DS, Hoffer PB, Innis RB, Bradberry CW (1997b) Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman pri-mates. Synapse 25:1-14 (Pubitemid 27014356)
142. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, Mailman RB (1999) Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and seroto-nin receptor subtypes. Neuropsychopharmacol20:612-627 (Pubitemid 29189265)
143. 2 receptor co-activation generates a novel phospholipase C-mediated calcium signal. J Biol Chem 279:35671-35678 (Pubitemid 39100570)
144. 2-like receptors. Can they be classified with the available antagonists? Brit J Pharmacol 88:585-593
145. 2-recep-tor. Implication of an original filter method. J Receptor Res 4:817-845 (Pubitemid 15155105)
146. 2-dopaminergic recep-tors in the primate cerebral cortex. Proc Natl Acad Sci USA 91:4353-4356
147. 4 dopamine receptor mRNAs in the primate cerebral cortex vs neostriatum: effects of chronic treatment with typical and atypical antipsychotic drugs. J Pharmacol Exp Ther 283:939-946 (Pubitemid 27514658)
148. Lieberman JA, Kane JM, Alvir J (1987) Provocative tests with psy-chostimulant drugs in schizophrenia. Psychopharmacology 91:415-433 (Pubitemid 17038204)
149. Lindgren N, Usiello A, Goiny M, Haycock J, Erbs E, Greengard P, Hokfelt T, Borrelli E, Fisone G (2003) Distinct roles of dopamine D2L and D2S receptor isoforms in the regulation of protein phos-phorylation at presynaptic and postsynaptic sites. Proc Natl Acad SciUSA 100:4305-4309 (Pubitemid 36418198)
150. 2- adrenoceptor agonism. Brit J Clin Pharmacol 54:231-245
151. Liu YF, Civelli O, Grandy DK, Albert PR (1992) Differential sensi-tivity of the short and long human dopamine D2 receptor subtypes to protein kinase C. J Neurochem 59:2311-2317
152. Luttrell LM, Lefkowitz RJ (2002) The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor sig-nals. J Cell Sci 115:455-465 (Pubitemid 34182973)
153. Mager DE, Wyska E, Jusko WJ (2003) Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos 31:510-519
154. Malany S, Hernandez LM, Smith WF, Crowe PD, Hoare SRJ (2009) Analytical method for simultaneously measuring ex vivo drug receptor occupancy and dissociation rate: application to (R)-dimethindene occupancy of central histamine H1 receptors. J Recept Sig Transd Res 29:84-93
155. 2A and D3 receptors: effects ofions and guanine nucleotides. J Pharmacol Exp Ther 274:790-797
156. 2 receptor Eur J Phar-macol 346:299-307 (Pubitemid 28234332)
157. Marchese A, Paing MM, Temple BR, Trejo J (2008) G protein coupled receptor sorting to endosomes and lysosomes. Annu Rev Pharma-col 48:601-629 (Pubitemid 351738165)
158. 2 receptor/ beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci USA 105:13656-13661
159. Meibohm B, DerendorfH (1997) Basic concepts ofpharmacokinetic/ pharmacodynamic (PK/PD) modelling. Int J Clin Pharm Th 35:401-413 (Pubitemid 27462583)
160. Meller E, Bohmaker K, Namba Y, Friedhoff AJ, Goldstein M (1987) Relationship between receptor occupancy and response at striatal dopamine autoreceptors. Mol Pharmacol 31:592-598 (Pubitemid 17101582)
161. Meller E, Enz A, Goldstein M (1988) Absence of receptor reserve at striatal dopamine receptors regulating cholinergic neuronal activ-ity. Eur J Pharmacol 155:151-154
162. Meltzer HY (1999) The role of serotonin in antipsychotic drug action. Neuropsychopharmacol 21:106S-115S (Pubitemid 29396478)
163. Meltzer HY (2002) Mechanism of action of atypical antipsychotic drugs. In: Davis KL, Charney D, Coyle JT, Nemeroff C (eds) Neuropsychopharmacology: the fifth generation of progress. Lippincott Williams & Wilkins, Philadelphia, pp 819-831
164. Miyake N, Thompson J, Skinbjerg M, Abi-Dargham A (2010) Presyn-aptic dopamine in schizophrenia. CNS Neurosci Ther 17:104-109
165. Miyamoto S, Duncan GE, Marx CE, Lieberman JA (2005) Treatments for schizophrenia: a critical review of pharmacology and mecha-nisms of action ofantipsychotic drugs. Mol Psychiat 10:79-104 (Pubitemid 40139590)
166. Mogenson GJ, Jones DL, Yim CY (1980) From motivation to action: functional interface between the limbic system and the motor system. Prog Neurobiol 14:69-97 (Pubitemid 10053405)
167. Mogenson GJ, Yang CR, Yim CY (1988) Influence ofdopamine on limbic inputs to the nucleus accumbens. Ann N Y Acad Sci 537:86-100 (Pubitemid 19029536)
168. qo5. Biochem Pharmacol 68:761-772 (Pubitemid 38953458)
169. Morsing P, Adler G, Brandt-Eliasson U, Karp L, Ohlson K, Renberg L, Sjöquist PO, Abrahamsson T (1999) Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension 33:1406-1413 (Pubitemid 29282662)
170. Motulsky HJ, Mahan LC (1984) The kinetics of competitive radio-ligand binding predicted by the law ofmass action. Mol Pharma-col 25:1-9 (Pubitemid 14223246)
171. 2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using [ F]-fallypride. Neuropsychopharmacol25:476-488 (Pubitemid 32830952)
172. 2 receptor antagonistradiotracer [ C]-raclopride. Synapse 52:188-208 (Pubitemid 38581669)
173. 11 C]raclopride in baboons. J Pharmacol Exp Ther 315:80-90 (Pubitemid 41380500)
174. 2-adrenergic receptors in purified membranes from human platelets. Implications of receptor-inhibitory nucleotide-binding protein stoichiometry. Mol Pharmacol 28:475-486 (Pubitemid 16224253)
175. 2 adrenergic receptors: evidence for a precoupled receptor.guanine nucleotide protein complex. Biochemistry 27:2374-2384
176. +/H+ exchange assessed by quantification of extracellular acidification. J Biol Chem 267:25748-25753 (Pubitemid 23013972)
177. 2 receptor dimers and receptor-blocking peptides. Biochem Biophys Res Commun 227:200-204 (Pubitemid 26370576)
178. 2 dopamine receptors. Neuropharmacology 47:860-872 (Pubitemid 39440980)
179. 2 receptors? J Neural Transm 92:213-220 (Pubitemid 23210664)
180. 2-dopa-mine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology 106:433-438
181. Ojima M, Inada Y, Shibouta Y, Wada T, Sanada T, Kubo K, Nishikawa K (1997) Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. Eur J Pharmacol 319:137-146 (Pubitemid 27051327)
182. Oldham WM, Hamm HE (2008) Heterotrimeric G-protein activation by G-protein-coupled receptors. Nat Rev Mol Cell Biol 9:60-71
183. Olsen CK, Brennum LT, Kreilgaard M (2008) Using pharmacokinetic- pharmacodynamic modelling asatool for prediction of therapeu-tic effective plasma levels of antipsychotics. Eur J Pharmacol 584:318-327
184. Olson T (2005) Does clozapine work by blocking spikes and sparing bursts? Med Hypotheses 65:68-78 (Pubitemid 40704533)
185. Olsson H, Farde L (2001) Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy-a simulation study based on experimental data. NeuroImage 14:936-945 (Pubitemid 32929894)
186. Ostrom RS (2002) New determinants of receptor-effector coupling: trafficking and compartmentation in membrane microdomains. Mol Pharmacol 61:473-476 (Pubitemid 34171912)
187. Ostrom RS, Post SR Insel PA (2000) Stoichiometry and compartmentation in G protein-coupled receptor signaling: implications for therapeutic interventions involving Gs. J Pharmacol Exp Ther 294:407-412 (Pubitemid 30490809)
188. Packeu A, De Backer J-P, Van Liefde I, Vanderheyden P, Vauquelin G (2008) Antagonist-dopamine D2L-receptor interactions in intact cells. Biochem Pharmacol 75:2192-2203
189. Packeu A, Béghin T, De Backer J-P, Vauquelin G (2010a) Antagonist-D2S-dopamine receptor interactions in intact recombinant Chinese hamster ovary cells. Fund Clin Pharmacol 24:293-303, 513 (title correction)
190. Packeu A, De Backer J-P, Vauquelin G (2010b) Non-competitive interaction between raclopride and spiperone on human D2L-receptors in intact recombinant Chinese hamster ovary cells. Fund Clin Pharmacol 24:283-291
191. Packeu A, Wennerberg M, Ballendran A, Vauquelin G (2010c) Estima-tion of the dissociation rate ofunlabelled ligand-receptor complexes by a "two-step" competition binding approach. Brit J Pharmacol 161:1311-1328
192. Paspalas CD, Rakic P, Goldman-Rakic PS (2006) Internalization of D2 dopamine receptors is clathrin-dependent and select to dendro-axonic appositions in primate prefrontal cortex. Eur J Neurosci 24:1395-1403 (Pubitemid 44401662)
193. Pauwels PJ, Tardif S, Wurch T, Colpaert FC (2001a) Real-time anal-ysis of dopamine: antagonist interactions at recombinant human D2long receptor upon modulation of its activation state. Brit J Pharmacol 134:88-97 (Pubitemid 32835471)
194. Pauwels PJ, Finana F, Tardif S, Wurch T, Colpaert FC (2001b) Dy-namic dopamine-antagonist interactions at recombinant human dopamine D2short receptor: dopamine-bound versus antagonist-bound receptor states. J Pharmacol Exp Ther 297:133-140 (Pubitemid 32242572)
195. Pettersson F, Pontén H, Waters N, Waters S, Sonesson C (2010) Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpi-peridine (huntexil, pridopidine, ACR16). J Med Chem 53:2510-2520
196. Petty RG (1999) Prolactin and antipsychotic medications: mechanism ofaction. Schizophr Res 35:S67-S73 (Pubitemid 29133027)
197. Pierce KL, Lefkowitz RJ (2001) Classical and new roles of beta-arrestins in the regulation of G-protein-coupled receptors. Nat Rev Neurosci 2:727-733 (Pubitemid 33674818)
198. Pike LJ (2003) Lipid rafts: bringing order to chaos. J Lipid Res 44:655-667 (Pubitemid 37279667)
199. Pilowsky LS, Mulligan RS, Acton PD, Ell PJ, Costa DC, Kerwin RW (1997) Limbic selectivity ofclozapine. Lancet 350:490-491
200. Ploeger BA, van der GraafPH, DanhofM (2009) Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling. Drug Metab Pharmacok 24:3-15
201. Raleigh F (1996) Use ofnovel antipsychotic drugs. Pharmacotherapy 16:160S-165S
202. s, J Biol Chem; 263: 9482-9485.
203. Rayport S, Sulzer D (1995) Visualization ofantipsychotic drug binding to living mesolimbic neurons reveals D2 receptor, acidotropic, and lipophilic components. JNeurochem 65:691-703
204. Remington G, Kapur S (2000) Atypical antipsychotics: are some more atypical than others? Psychopharmacology 148:3-15 (Pubitemid 30062465)
205. Rhodes DG, Sarmiento JG, Herbette LG (1985) Kinetics ofbinding of membrane-active drugs to receptor sites. Diffusion-limited rates for a membrane bilayer approach of 1,4-dihydropyridine calcium chan-nel antagonists to their active site. Mol Pharmacol 27:612-623 (Pubitemid 15010692)
206. Rice ME, Cragg SJ (2008) Dopamine spillover after quantal release: rethinking dopamine transmission in the nigrostriatal pathway Brain Res Rev 58:303-313
207. Robert V Pinton P, Tosello V, Rizzuto R, Pozzan T (2000) Recombinant aequorin as tool for monitoring calcium concentration in subcellular compartments. Meth Enzymol 327:440-456 (Pubitemid 34193326)
208. Roberts DJ, Strange PG (2005) Mechanisms of inverse agonist action at D2 dopamine receptors. Brit J Pharmacol 145:34-42 (Pubitemid 40675546)
209. Roberts DJ, Lin H, Strange PG (2004a) Investigation of the mechanism of agonist and inverse agonist action at D2 dopamine receptors. Biochem Pharmacol 67:1657-1665 (Pubitemid 38479844)
210. Roberts DJ, Lin H, Strange PG (2004b) Mechanisms of agonist action at D2 dopamine receptors. Mol Pharmacol 66:1573-1579 (Pubitemid 39564783)
211. Salimpoor VN, Benovoy M, Larcher K, Dagher Aand Zatorre RJ (2010) Anatomically distinct dopamine release during anticipa-tion and experience of peak emotion to music. Nat Neurosci 14:257-262
212. Samama P, Cotecchia S, Costa Tand Lefkowitz RJ (1993) A mutation-induced activated state of the beta2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 268:4625-4636 (Pubitemid 23081571)
213. Sanger DJ (2004) The search for novel antipsychotics: pharmacolog-ical and molecular targets. Expt Opin Ther Tar 8:631-641 (Pubitemid 40028371)
214. Schmidt M, Jansens L, Kent J, Anghelecu I, Husken G, Sinha V Mannaert E (2010) Efficay and safety of JNJ-37822681, a fast-dissociating D2 antagonist in the treatment of schizophrenia. Eur Neuropsychopharmacol 20:S484-S485
215. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptorbinding. Psychopharmacology 124:57-73 (Pubitemid 26112775)
216. Schultz W (2007) Multiple dopamine functions at different time courses. Annu Rev Neurosci 30:259-288 (Pubitemid 47218758)
217. Seeman P (1992) Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuro-psychopharmacol 7:261-284
218. Seeman P (1995) Therapeutic receptor-blocking concentrations of neuroleptics. Int Clin Psychopharmacol 10(Suppl 3):5-13 (Pubitemid 26054876)
219. Seeman P (2002) Atypical antipsychotics: mechanism ofaction. Can J Psychiat 47:27-38
220. Seeman P (2005) An update offast-offdopamine D2 atypical antipsy-chotics. Am J Psychiat 162:1984-1985
221. Seeman P (2008) Dopamine D2High receptors on intact cells. Synapse 62:314-318 (Pubitemid 351365005)
222. Seeman P (2009) Dopamine D2 Hig receptors measured ex vivo are elevated in amphetamine-sensitized animals. Synapse 63:186-192
223. Seeman P (2011) All roads to schizophrenia lead to dopamine super-sensitivity and elevated dopamine D2 Hig receptors. CNS Neuro-sci Ther 17:118-132
224. Seeman P, Kapur S (1997) Clozapine occupies high levels ofdopamine D2 receptors. Life Sci 160:PL207-PL216
225. Seeman P, Tallerico T (1998) Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels ofthese receptors. Mol Psychiat 3:123-134 (Pubitemid 28149553)
226. Seeman P, Tallerico T (1999) Rapidrelease ofantipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupan-cy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiat 156:876-884 (Pubitemid 29260342)
227. Seeman P, Van Tol HH (1995) Deriving the therapeutic concen-trations for clozapine and haloperidol: the apparent dissociation constant of a neuroleptic at the dopamine D2 or D4 receptor varies with the affinity of the competing radioligand. Eur J Pharmacol 291:59-66
228. Seeman P, Chau-Wong M, Tedesco J, Wong K (1975) Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Nat Acad Sci USA 72:4376-4380
229. Seeman P, Lee T, Chau-Wong M, Wong K (1976) Antipsychotic drug doses and neurolepticrdopamine receptors. Nature 261:717-719
230. 2 receptor reveals different densities for dopamine receptor antagonist ligands. Implications for human brain positron emission tomography. Eur J Pharmacol 227:139-146
231. Seeman P, Corbett R, Nam D, Van Tol HHM (1996) Dopamine and serotonin receptors: amino acid sequences, and clinicalroleinneu-roleptic parkinsonism. Jpn J Pharmacol 71:187-204 (Pubitemid 26264263)
232. 4 receptors. Neuropsychopharmacol 16:93-110, discussion 111-135 (Pubitemid 27088199)
233. Seeman P, Nam D, Ulpian C, Liu IS, Tallerico T (2000) New dopamine receptor, D2(Longer), with unique TG splice site, in human brain. Brain Res Mol Brain Res 76:132-141 (Pubitemid 30133241)
234. hig receptors occupied by endogenous dopamine, even in the absence of acute challenges. Synapse 46:235-239 (Pubitemid 35239745)
235. 2 receptor, but not [ H]raclopride or [ H]spiperone in isotonic medium: implications for human positron emission tomography. Synapse 49:209-215 (Pubitemid 36927961)
236. high dopamine receptors. Synapse 60:319-346 (Pubitemid 44134353)
237. 11C]raclopride. Synapse 59:260-269 (Pubitemid 43271734)
238. 2 receptor-like immunoreactivity in midbrain dopamine neurons and their striatal targets. J Neurosci 14:88-106
239. Sesack SR, Carr DB, Omelchenko N, Pinto A (2003) Anatomical substrates forglutamate-dopamine interactions: evidence for spec-ificity of connections and extrasynaptic actions. Ann N Y Acad Sci 1003:36-52 (Pubitemid 38083044)
240. Severne Y, Coppens D, Bottari S, Riviere M, Kram R, Vauquelin G (1984) The influence of the beta-adrenergic receptor concentra-tion on their functional coupling to the adenylate cyclase system. Proc Natl Acad Sci USA 81:4637-4641 (Pubitemid 14065130)
241. Severne Y, IJzerman A, Nerme V, Zimmerman H, Vauquelin G (1986) Shallow agonist competition binding curves for beta-adrenergic receptors: the role for tight agonist binding. Mol Pharmacol 31:69-73 (Pubitemid 17016419)
242. Sibley DR (1995) Molecular biology ofdopamine receptors. In: Ariano MA, Surmeier DJ (eds) Molecular and cellular mechanisms of neostriatal function. Landes RG, Austin, pp 255-272
243. Sibley DR, LeffSE, Creese I (1982) Interactions ofnovel dopaminer-gic ligands with D-1 and D-2 dopamine receptors. Life Sci 31:637-645 (Pubitemid 12032400)
244. Sibley DR, Mahan LC, Creese I (1983) Dopamine receptor binding on intact cells. Absence of a high-affinity agonist-receptor binding state. Mol Pharmacol 23:295-302 (Pubitemid 13116851)
245. 2 dopamine receptor signaling. Poster, presented at the19th Congress of the European Congress ofPsychiatry; Prague, 3/2011. Eur Psychiat 26(suppl 1):910
246. 2 dopamine receptor internalization prolongs the decrease ofradioligand bind-ing after amphetamine: a PET study in a receptor internalization-deficient mouse model. NeuroImage 50:1402-1407
247. 2 and D3 dopamine receptors. Synapse 63:462-475
248. 7 serotonin receptor. Mol Pharmacol 70:1264-1270 (Pubitemid 44435978)
249. Spivak CE, Oz M, Beglan CL, Shrager RI (2006) Diffusion delays and unstirred layer effects at monolayer cultures of Chinese hamster ovary cells: radioligand binding, confocal microscopy, and math-ematical simulations. Cell Biochem Biophys 45:43-58 (Pubitemid 43780381)
250. Sternweis PC, Robishaw JD (1984) Isolation of two proteins with high affinity for guanine nucleotides from membranes of bovine brain. J Biol Chem 259:13806-13813 (Pubitemid 15224957)
251. 2 receptor occu-pancy in vivo. Psychopharmacology 160:107-112 (Pubitemid 34169832)
252. Surmeier DJ, Song WJ, Yan Z (1996) Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J Neu-rosci 16:6579-6591 (Pubitemid 26337379)
253. Swinney DC (2004) Biochemical mechanisms of drug action: what does it take for success? Nat Rev Drug Discov 3:801-808 (Pubitemid 39242832)
254. Swinney DC (2006a) Biochemical mechanisms of new molecular entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and safety. Curr Top Med Chem 6:461-478
255. Swinney DC (2006b) Can binding kinetics translate to a clinically differentiated drug? From theory to practice. Lett Drug Des Dis-cov 3:569-574 (Pubitemid 44544011)
256. Swinney DC (2008) Applications of binding kinetics to drug discov-ery: translation ofbinding mechanisms to clinically differentiated therapeutic responses. Int J Pharm Med 22:23-34
257. Swinney DC (2009) The role of binding kinetics in therapeutically useful drug action. Curr Opin Drug Disc Dev 12:31-39
258. 2-adrenoceptor agonist salmeterol. Brit J Pharmacol 158:183-194
259. 2 receptors. Eur J Pharmacol 607:35-40
260. 11 C]FLB 457. Am J Psychiat 58:926-930 (Pubitemid 32547623)
261. Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S (2002) Significant dissociation of brain and plasma kinetics with anti-psychotics. Mol Psychiatr 7:317-321 (Pubitemid 34280640)
262. 2 receptor Bioorg Med Chem 19:2231-2241
263. Tummino PJ, Copeland RA (2008) Residence time ofreceptor-ligand complexes and its effect on biological function. Biochemistry 47:5481-5492 (Pubitemid 351711169)
264. Turrone P, Kapur S, Seeman MV, Flint AJ (2002) Elevation of prolactin levels by atypical antipsychotics. Am J Psychiat 159:133-135
265. 11 protein-coupled receptors. J Biol Chem 284:16914-16921
266. 2 receptors. Nature 408:199-203
267. + concentration decrease in GH4C1 cells. J Biol Chem 265:10320-10326
268. van Os J, Kapur S (2009) Schizophrenia. Lancet 374:635-645
269. Van Rossum JM (1967) The significance ofdopamine-receptorblockade for the action ofneuroleptic drugs. In: Brill H, Cole JO, Deniker P, Hippius H, Bradley PB (eds) Neuro-psycho-pharmacology, Pro-ceedings of the 5th Int. Congress of the Collegium Internationale Neuro-Psycho-pharmacologicum, March 1966. Excerpta Medica Foundation, Amsterdam, pp321-329
270. 2 and D3 receptors in Chinese hamster ovary cells. J Pharmacol Exp Ther 290:908-916 (Pubitemid 29344592)
271. Vauquelin G (2010) Rebinding: or why drugs may act longer in vivo than expected from their in vitro target residence time. Expert Opin Drug Discov 5:927-941
272. Vauquelin G, Charlton S (2010) Long-lasting target binding and rebind-ing as mechanisms to prolong in vivo drug action. Brit J Pharmacol 161:488-508
273. Vauquelin G, Maguire ME (1980) Inactivation of beta-adrenergic receptors by N-ethylmaleimide in S49 lymphoma cells: receptor heterogeneity in relation to coupling to adenylate cyclase. Mol Pharmacol 18:362-369 (Pubitemid 11205361)
274. Vauquelin G, Packeu A (2009) Ligands, their receptors and ... plasma membranes. Mol Cell Endocrinol 311:1-10
275. Vauquelin G, Szczuka A (2007) Kinetic versus allosteric mechanisms to explain insurmountable antagonism and delayed ligand disso-ciation. Neurochem Int 51:254-260 (Pubitemid 47374316)
276. Vauquelin G, Van Liefde I (2006) Slow antagonist dissociation and long-lasting in vivo receptor protection. Trends Pharmacol Sci 27:356-359
277. Vauquelin G, von Mentzer P (2007) In: Vauquelin G, von Mentzer B (eds) G-protein coupled receptors: Molecular pharmacology. John Wiley and Sons Ltd, Chichester, pp 53-64, 163-175 and 185-191
278. Vauquelin G, Severne Y, Convents A, Nerme V, Abrahamsson T (1988) Agonist-mediated activation of adrenergic receptors. In: Melchiorre C, Giannella M (eds) Recent advances in receptor chemistry. Elsevier Science Publishers, Amsterdam, pp 43-61
279. Vauquelin G, Morsing P, Fierens FLP, De Backer JP, Vanderheyden PML (2001) A two-state receptor model for the interaction between angiotensin II AT1 receptors and their non-peptide antag-onists. Biochem Pharmacol 61:277-284 (Pubitemid 32126665)
280. Vauquelin G, Van Liefde I, Vanderheyden P (2002a) Models and methods for studying insurmountable antagonism. Trends Phar-macol Sci 23:514-518 (Pubitemid 35292371)
281. Vauquelin G, Van Liefde I, Birzbier BB, Vanderheyden PML (2002b) New insights in insurmountable antagonism. Fund Clin Pharma-col 16:263-272 (Pubitemid 35205336)
282. Vauquelin G, Fierens F, Van Liefde I (2006) Long-lasting AT1 receptor binding and protection by candesartan: comparison to other biphenyl-tetrazole sartans. J Hypertens 24:S23-S30
283. Verheijen I, Tourlousse D, Vanderheyden PML, De Backer JP, Vauquelin G (2004) Effect of saponin and filipin on antagonist binding to AT1 receptors in intact cells. Biochem Pharmacol 67:601-606
284. ong receptor-deficient mice display altera-tions in striatum-dependent functions. J Neurosci 20:8305-8314
285. Weinberger DR, Laruelle M (2001) Neurochemical and neuropharma-cological imaging in schizophrenia. In: Davis KL, Charney D, Coyle JT, Nemeroff C (eds) Neuropsychopharmacology: the fifth generation ofprogress. Lippincott Williams & Wilkins, Philadel-phia, pp 833-855
286. 2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther 299:268-276 (Pubitemid 32905144)
287. 4 receptor ligands: relation to antipsychotic action. Eur J Pharmacol 351:273-286 (Pubitemid 28321462)
288. 2 dopamine receptor that adopts the activated conformation. J Neurochem 77:493-504 (Pubitemid 32298744)
289. 2 dopa-mine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Brit J Psychiat 179:503-508 (Pubitemid 34031674)
290. 2 dopamine receptors in the basal ganglia of the rat: light and electron micros-copy. Neuroscience 65:709-730
291. Zhang R, Monsma F (2009) The importance of drug-target residence time. Curr Opin Drug Discov Devel 12:488-496
292. Zhang R, Monsma F (2010) Binding kinetics and mechanism ofaction: toward the discovery and development of better and best in class drugs. Expert Opin Drug Discov 5:1023-1029